In May 2026, the U.S. Department of Health and Human Services (HHS) announced an initiative to tackle what it terms "psychiatric overprescribing," with a focus on antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) such as Prozac, Zoloft, Paxil, and Lexapro. These medications are widely prescribed for a variety of conditions including major depression, anxiety disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder, panic disorder, premenstrual dysphoric disorder, neuropathic pain, and fibromyalgia.

Contrary to some alarming reports, HHS has not banned antidepressants nor advised current users to discontinue their medications. The agency's stated goal is to "promote appropriate psychiatric prescribing" and support "deprescribing when clinically indicated." However, there is concern that the initiative might unintentionally limit access to these medications, as "better prescribing" can be confused with "less prescribing."

Antidepressants are easier to start than to stop; discontinuation often requires multiple medical visits, gradual dose reductions, symptom monitoring, and clinical expertise to differentiate withdrawal symptoms from relapse. According to a 2025 survey reported in BMJ Mental Health in 2026, 16.6 percent of American adults reported current antidepressant use, with usage higher among women, especially those aged 60 or older, where 24.3 percent reported past-month use.

Short-term trial data indicate that 4 percent of minors treated with antidepressants reported suicidal ideation compared to 2 percent on placebo, though no completed suicides were reported. Some analyses suggest that common side effects of antidepressants may overlap with depressive symptoms, potentially understating their effects.

Critics argue that antidepressants represent a way for the medical system to generate recurring revenue without addressing the root causes of depression. The HHS initiative aims to balance appropriate prescribing with clinical needs, but the risk remains that it could lead to restricted access for patients who benefit from these medications.

Sources